HOOKIPA Pharma Inc (HOOK)
0.7611
-0.04
(-5.51%)
USD |
NASDAQ |
Mar 24, 16:00
0.7501
-0.01
(-1.45%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 41.65M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -55.75% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.495 |
| Price to Book Value | 0.4063 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0244 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
03/20 09:19
Yahoo
03/15 07:00
Globe Newswire
03/15 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/15/2024* | 08:30 EST | Earnings Call | Q4 2023 | -- | -- | -- | |
| 05/16/2023* | -- | Results | Q1 2023 | -- | -0.23 | -- | |
| 03/15/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/15/2023 | -- | Results | Q4 2022 | -0.16 | -0.25 | 36.00% | |
| 11/14/2022 | -- | Results | Q3 2022 | -0.25 | -0.30 | 16.11% | |
| 08/11/2022 | -- | Results | Q2 2022 | -0.23 | -0.36 | 36.11% | |
| 05/16/2022 | -- | Results | Q1 2022 | -0.40 | -0.30 | -34.45% | |
| 03/24/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |
| URL | https://www.hookipapharma.com |
| Investor Relations URL | https://ir.hookipapharma.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | 14.25M |
| Total Expenses (TTM) | 79.49M |
| Net Income (TTM) | -64.92M |
| Total Assets (Quarterly) | 170.45M |
| Total Liabilities (Quarterly) | 67.94M |
| Shareholders Equity (Quarterly) | 102.52M |
| Cash from Operations (TTM) | -20.00M |
| Cash from Investing (TTM) | -5.017M |
| Cash from Financing (TTM) | 72.27M |
Ratings
Profile
Edit
| HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |
| URL | https://www.hookipapharma.com |
| Investor Relations URL | https://ir.hookipapharma.com/ |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 16, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| HOOK Tweets |